Overview A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer Status: Unknown status Trial end date: 2015-06-01 Target enrollment: Participant gender: Summary Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in Patients with Advanced Metastatic Cancer Phase: Phase 1 Details Lead Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics